Pierre Legault Biography and Net Worth

Director of Syndax Pharmaceuticals

Pierre Legault has served as a member of our board of directors since January 2017. Mr. Legault currently serves on the board of Bicycle Therapeutics (Chairman) and Poxel Pharmaceuticals (Chairman), each of which is a publicly traded company, as well as the boards of several private companies. Previously, he served on the board of Urovant Sciences, Clementia Pharmaceuticals, Armo BioSciences, Tobira Therapeutics, NPS Pharmaceuticals, Forest Laboratories, Cyclacel Pharmaceuticals, Eckerd Pharmacy, Regado Biosciences, NephroGenex and several others. Mr. Legault served as Chairman of NephroGenex from 2012 through 2013 and Chief Executive Officer from 2014 through 2016, as Chief Executive Officer of Prosidion from 2010 through 2012, and Executive Vice President, Chief Financial Officer, and Treasurer of OSI Pharmaceuticals from 2009 through 2010. His prior senior executive experience also includes serving as President of Eckerd Pharmacy and as Executive Vice President and Chief Administrative Officer of Rite Aid Corporation. Mr. Legault studied at McGill University, HEC Montreal and Harvard Business School. He holds an MBA, BAA, CA, CPA and Six Sigma Green Belt diplomas.

What is Pierre Legault's net worth?: The estimated net worth of Pierre Legault is at least $510,400.00 as of January 12th, 2023. Mr. Legault owns 32,000 shares of Syndax Pharmaceuticals stock worth more than $510,400 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Legault may own. Learn More about Pierre Legault's net worth.
How do I contact Pierre Legault?: The corporate mailing address for Mr. Legault and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]. Learn More on Pierre Legault's contact information.
Has Pierre Legault been buying or selling shares of Syndax Pharmaceuticals?: Pierre Legault has not been actively trading shares of Syndax Pharmaceuticals within the last three months. Most recently, Pierre Legault sold 24,000 shares of the business's stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $26.74, for a transaction totalling $641,760.00. Following the completion of the sale, the director now directly owns 32,000 shares of the company's stock, valued at $855,680. Learn More on Pierre Legault's trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Pierre Legault (Director), Michael Metzger (COO), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, Syndax Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,250 shares worth more than $25,037.50. The most recent insider tranaction occured on June, 14th when CFO Keith A Goldan bought 1,250 shares worth more than $25,037.50. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 6/14/2024.

Pierre Legault Insider Trading History at Syndax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/12/2023	Sell	24,000	$26.74	$641,760.00	32,000
12/22/2021	Sell	24,000	$22.01	$528,240.00
12/20/2021	Sell	20,000	$21.01	$420,200.00

Pierre Legault Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $15.95

$15.34

$16.19

50 Day Range

MA: $18.76

$15.77

$21.81

2 Week Range

Now: $15.95

$14.97

$25.34

Volume

1,261,777 shs

Average Volume

2,036,181 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>